MARY PORTER: Open Payments
NPI 1356489272 · FLOWOOD, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,225 in 75 payments from 17 companies in 2025. Trend: 2023 $791 · 2024 $912 · 2025 $1,225
Food & beverage: $1,225
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $215 |
| PFIZER INC. | 10 | $156 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $147 |
| Astellas Pharma US Inc | 6 | $133 |
| Novo Nordisk Inc | 4 | $79 |
| Ardelyx, Inc. | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 4 | $72 |
| AstraZeneca Pharmaceuticals LP | 3 | $62 |
| Axsome Therapeutics, Inc. | 2 | $41 |
Products named: CAPLYTA, Veozah, UBRELVY, NURTEC ODT, VRAYLAR, Ozempic, IBSRELA, TRINTELLIX.
Industry payments across MS — which companies pay providers there.
